GT Biopharma (GTBP) Liabilities and Shareholders Equity (2010 - 2026)

GT Biopharma (GTBP) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 276.07% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $29.5 million (up 116.48% YoY), while the FY2025 annual figure was $8.1 million, up 91.54% from the prior year.
• Liabilities and Shareholders Equity grew to $10.0 million in Q1 2026 per GTBP's latest filing, from $8.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $27.4 million in Q1 2022 and bottomed at $2.7 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $13.2 million across 5 years, with a median of $12.1 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity tumbled 73.18% — and 2026, when it soared 276.07%.
• GT Biopharma's Liabilities and Shareholders Equity stood at $16.7 million in 2022, then declined by 15.7% to $14.1 million in 2023, then plunged by 70.0% to $4.2 million in 2024, then surged by 91.54% to $8.1 million in 2025, then advanced by 23.32% to $10.0 million in 2026.
• Business Quant data shows GTBP's Liabilities and Shareholders Equity at $10.0 million in Q1 2026, $8.1 million in Q4 2025, and $4.3 million in Q3 2025.